KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Revenue (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Revenue data on record, last reported at $3.9 billion in Q4 2025.

  • For Q4 2025, Revenue rose 37093.33% year-over-year to $3.9 billion; the TTM value through Dec 2025 reached $14.3 billion, up 109.68%, while the annual FY2025 figure was $14.3 billion, 0.99% up from the prior year.
  • Revenue reached $3.9 billion in Q4 2025 per REGN's latest filing, up from $3.8 billion in the prior quarter.
  • Across five years, Revenue topped out at $8.5 billion in Q3 2021 and bottomed at -$18.9 million in Q2 2023.
  • Average Revenue over 5 years is $2.2 billion, with a median of $2.8 billion recorded in 2021.
  • Peak YoY movement for Revenue: plummeted 137.8% in 2023, then soared 37093.33% in 2025.
  • A 5-year view of Revenue shows it stood at $8.5 billion in 2021, then tumbled by 98.82% to $100.0 million in 2022, then tumbled by 118.3% to -$18.3 million in 2023, then skyrocketed by 42.62% to -$10.5 million in 2024, then skyrocketed by 37093.33% to $3.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $3.9 billion in Q4 2025, $3.8 billion in Q3 2025, and $3.7 billion in Q2 2025.